Company intelligence / Profile preview

BioView

Ownership: Private
Development stage: Commercial

Overview

BioView’s automated cell imaging and analysis solutions—including the FDA-cleared DUET platform—are commercially available worldwide. Their systems have been validated by leading institutes for use in clinical diagnostics (e.g., cancer detection via FISH) as well as research settings. The Allegro Plus system advances liquid biopsy workflows by automating circulating tumor cell (CTC) detection with high throughput and adaptability to multiple assay types. No direct clinical trial results apply since these are diagnostic devices.

Modalities: DeviceDiagnostic platform
Industry: Pathology

Partnerships

Abbott Molecular (international distribution partner)

Beyond the preview

Go deeper on BioView.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioView.

Explore the full profile